BN
Benitec Biopharma Inc.
BNTC · NASDAQ
$12.19 -2.01% (-$0.25)
1M -2.95%
Market Cap $419.8M
P/E Ratio -
Div. Yield -
ROE 34.82%
Bulios Fair Price
$11.46
6.0% downside
Current Price
$12.19
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BNTC is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/B 2.29x
P/S 755.05x
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 223.20%
Rev. growth N/A
FCF growth N/A
Profitability
0 /100
Weak Net margin 8,792.09%
Op. margin 9,701.08%
FCF margin 3,704.13%
Quality
0 /100
Poor ROE 34.82%
ROA 26.14%
Asset turnover 0.00x
Debt
100 /100
Low Current ratio 56.82x
Int. coverage 15.69x
Debt/Equity 0.00x
Stability
37 /100
Moderate EPS volatility 27.36%
Profitable years 0
Beta 0.26x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BNTC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jerel A. Banks
Employees
19
Headquarters
Hayward
Upcoming events
28 SEP
Earnings
Upcoming earnings report